Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Phase 2 Recruiting
20 enrolled
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
Phase 2 Recruiting
27 enrolled
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
Phase 2 Recruiting
50 enrolled
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Recruiting
43 enrolled
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Phase 2 Recruiting
40 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
BRAZAN
Phase 2 Recruiting
60 enrolled
GLOASIS
Phase 2 Recruiting
100 enrolled
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Phase 2 Recruiting
60 enrolled
FIL_COLUMN
Phase 2 Recruiting
49 enrolled
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Recruiting
80 enrolled
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Phase 2 Recruiting
27 enrolled
IMCL-2023
Phase 2 Recruiting
50 enrolled
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Phase 2 Recruiting
25 enrolled
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Phase 2 Recruiting
27 enrolled
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Recruiting
36 enrolled
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Phase 2 Recruiting
68 enrolled
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Phase 2 Recruiting
20 enrolled
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Phase 2 Recruiting
30 enrolled
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Recruiting
30 enrolled
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
Phase 2 Recruiting
40 enrolled
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Phase 2 Recruiting
45 enrolled
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 Recruiting
300 enrolled
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
Phase 2 Recruiting
50 enrolled
DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 Recruiting
248 enrolled
ZEBRA
Phase 2 Recruiting
50 enrolled
CARAMEL
Phase 2 Recruiting
48 enrolled
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
Phase 2 Recruiting
105 enrolled
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
V-MIND
Phase 2 Recruiting
100 enrolled
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Phase 2 Recruiting
52 enrolled
ZGR
Phase 2 Recruiting
39 enrolled
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma
Phase 2 Recruiting
90 enrolled
CARMAN
Phase 2 Recruiting
150 enrolled
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
Phase 2 Recruiting
16 enrolled
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Phase 2 Recruiting
45 enrolled
GOlDiLOX
Phase 2 Recruiting
42 enrolled
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 2 Recruiting
23 enrolled
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)
Phase 2 Recruiting
98 enrolled